Understanding the Drivers of Antibiotic use in the Treatment of Childhood Diarrhea and Relationship to Antibiotic Resistance in China
了解中国儿童腹泻治疗中抗生素使用的驱动因素及其与抗生素耐药性的关系
基本信息
- 批准号:10688168
- 负责人:
- 金额:$ 13.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-22 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAffectAgeAntibiotic ResistanceAntibioticsAntimicrobial ResistanceAreaAutomobile DrivingBacterial Drug ResistanceBehavioralCalibrationCaregiversCharacteristicsChildChildhoodChinaClinicClinicalCommunitiesComplexCountryDataData AnalysesDevelopmentDiagnosticDiarrheaDiseaseDrug toxicityEconomicsEffectivenessEpidemiologyEquilibriumExposure toFaceFecesFutureGoalsHealth systemHouseholdHydration statusImmune systemImprove AccessIncentivesIncomeIndividualInfectious Disease EpidemiologyInterventionKnowledgeLearningLinkMachine LearningMarketingMentored Research Scientist Development AwardMentorsModelingMortality DeclineNatureOralOutcomes ResearchParentsPatientsPharmacistsPharmacy facilityPoliciesPopulationPositioning AttributePrevalencePsychological reinforcementQuality of CareQuasi-experimentRapid diagnosticsRecommendationResearchResearch ActivityResistanceResistance developmentRuralSeriesSideSocial SciencesSourceStandardizationStatistical Data InterpretationSuperbugSurveysSystemTechniquesTestingTimeTrainingTraining ActivityUnited States National Institutes of HealthWorkanalytical toolbacterial resistancebehavioral responsecare providerscareercommunity settingcommunity-level factorcostdesigndevelopment policydiarrheal diseaseeffective interventionexperienceexperimental studyglobal healthgut microbiotahealth care qualityhealth seeking behaviorinfectious disease modelinsightlow and middle-income countriesmodels and simulationpopulation basedpreventprogramssimulationsocialstructural determinants
项目摘要
ABSTRACT
By the age of 5, children in low and middle-income countries (LMICs) are exposed to nearly five times more
antibiotics than high-income country children. Although improved access to antibiotics has been a major driver
of mortality declines, most antibiotics administered to children are clinically unnecessary. Excessive use can
lead to adverse events, drug toxicity, and harm the gut microbiota and immune system. It also contributes to
antimicrobial resistance (AMR), the costs of which are disproportionately borne by children in LMICs. Although
widespread clinically unnecessary use of antibiotics in LMICs is well-documented, substantial knowledge gaps
remain regarding the drivers of overuse among children and how these are linked to the dynamics of
resistance and disease. This knowledge is required to design policies and interventions that appropriately
balance access and overuse. This K01 Award proposal focuses on identifying incentives that caregivers and
providers face to treat children with antibiotics and how these are related to the development of resistance. My
career goal is to become independent scholar working at the intersection of economics and infectious disease
epidemiology with a focus on research to inform AMR policies in LMICs. The proposed training activities build
on my background as an economist and experience conducting population-based experimental research with
further training in infectious disease epidemiology, the biomedical underpinnings of antimicrobial resistance,
machine learning techniques, and agent-based modeling of infectious disease and social systems. Aligned
with my training goals, my research program aims to integrate concepts from economics and infectious
disease epidemiology and to use state-of-the-art machine learning approaches to examine the complex
relationship between factors driving demand for antibiotics, disease, and the development of resistance. To do
so, I will draw on existing micro-level data from a survey of clinicians and households across 360 rural villages
in southwest China as well as new experimental data on the prescription practices of clinicians and
pharmacists in the same area. My specific research aims are 1) to experimentally evaluate the prescribing
practices of clinicians and pharmacists for pediatric diarrhea cases; 2) to estimate the influence of clinician
advice on antibiotic use in children, and how this varies with patient, clinician, and community characteristics;
and 3) to develop an agent-based model of health-seeking behavior, antibiotic use, and bacterial resistance for
pediatric diarrhea cases in rural China and use this model to conduct counterfactual simulations to prioritize
interventions for future study. My mentoring team has specialized training in infectious disease epidemiology,
the epidemiology of antimicrobial resistance, machine learning, and agent-based modeling as well as
experience leading interdisciplinary teams. This research will generate new insights that can inform policies to
better balance access to antibiotics and overuse. The training and research proposed in this K01 award will
support the development of future R-level proposals to study the design of AMR policies in LMICs.
摘要
到5岁时,低收入和中等收入国家(LMIC)的儿童接触到的风险几乎是
比起高收入的农村儿童,抗生素的比例更高。尽管抗生素获得的改善一直是一个主要的驱动力
在死亡率下降的情况下,大多数给儿童使用的抗生素在临床上是不必要的。过度使用可能会
导致不良事件、药物毒性,并损害肠道微生物区系和免疫系统。它还有助于
抗菌素耐药性(AMR),其费用不成比例地由LMIC中的儿童承担。虽然
在LMICs中广泛使用临床上不必要的抗生素是有充分证据的、实质性的知识差距
仍然关注儿童过度使用的驱动因素,以及这些驱动因素如何与
抵抗力和疾病。这种知识是设计适当的政策和干预措施所必需的
平衡访问和过度使用。本K01奖提案侧重于确定照顾者和
供应商面临着用抗生素治疗儿童的问题,以及这些与耐药性发展的关系。我的
职业目标是成为独立的学者,在经济学和传染病的交叉点上工作
流行病学,专注于为低收入国家的AMR政策提供信息的研究。拟议的培训活动建立
关于我作为一名经济学家的背景和进行基于人口的实验研究的经验
进一步培训传染病流行病学、抗菌素耐药性的生物医学基础,
机器学习技术,以及传染病和社会系统的基于代理的建模。对齐
根据我的培训目标,我的研究项目旨在将经济学和传染性的概念结合起来
疾病流行病学和使用最先进的机器学习方法来检查复杂的
推动抗生素需求、疾病和耐药性发展的因素之间的关系。去做
因此,我将利用360个农村的临床医生和家庭调查中现有的微观数据
在西南中国以及新的实验数据的处方实践中的临床医生和
同一地区的药剂师。我的具体研究目标是:1)对处方进行实验评估
临床医生和药师在儿科腹泻病例中的实践;2)评估临床医生的影响
关于儿童使用抗生素的建议,以及这如何随患者、临床医生和社区特征的不同而变化;
以及3)开发基于代理的健康行为、抗生素使用和细菌耐药性的模型
农村中国儿童腹泻病例调查及利用该模型进行反事实模拟
未来研究的干预措施。我的指导团队接受过传染病流行病学方面的专门培训,
抗菌素耐药性的流行病学、机器学习、基于代理的建模以及
有领导跨学科团队的经验。这项研究将产生新的见解,为政策提供信息
更好地平衡抗生素的使用和过度使用。本K01奖项中建议的培训和研究将
支持制定未来R级提案,以研究低收入中等收入国家AMR政策的设计。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sean Y Sylvia其他文献
Sean Y Sylvia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sean Y Sylvia', 18)}}的其他基金
Understanding the Drivers of Antibiotic use in the Treatment of Childhood Diarrhea and Relationship to Antibiotic Resistance in China
了解中国儿童腹泻治疗中抗生素使用的驱动因素及其与抗生素耐药性的关系
- 批准号:
10370831 - 财政年份:2022
- 资助金额:
$ 13.19万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 13.19万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 13.19万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 13.19万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 13.19万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 13.19万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 13.19万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 13.19万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 13.19万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 13.19万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 13.19万 - 项目类别: